/
Dermatology
Chronic Spontaneous Urticaria
19
Pipeline Programs↗
28
Active Trials↗
28
Companies Involved↗
Chronic Spontaneous Urticaria is an emerging landscape with 19 programs across 28 companies. The most active players are Novartis, Celldex Therapeutics, Taizhou Mabtech Pharmaceutical Co.,Ltd. 7 programs are in Phase 3.
Intelligence
Pipeline Metrics
Competitive Density
Pipeline Velocity
Mech. Concentration
Completion Rate
Attrition Rate
Competition
Competitive Landscape
Bubble size = clinical trials
Approved
Phase 3
Phase 2
Phase 1
Preclinical
Key Players
Top Companies Companies ranked by the number of pipeline programs they run for this disease.
Pipeline
Programs by Phase
Preclinical3
Phase 26
Phase 37
Approved
No programs
Analysis
Modality Breakdown
79%
Small molecule
11 of 14 classified programs — the dominant modality here.
Small molecule leads; the ring shows all 14 classified programs, each share of the total. Modality classified for 84% of 19 pipeline programs.
Analysis
Trial Status
79
clinical trials
Completed31 · 39%
Recruiting13 · 16%
Not yet recruiting9 · 11%
Terminated9 · 11%
Unknown status7 · 9%
Active, not recruiting5 · 6%
Other5 · 6%
Clinical Trials
Trial Activity
79 trials
Extending Omalizumab Treatment Intervals in Patients With Chronic Spontaneous Urticaria
Recruiting·—·Phase 4·NCT05916937·40 enrolled
Page 1 of 6
Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)